Up-regulation of ephrin-A1 during melanoma progression
- PMID: 10502726
- DOI: 10.1002/(sici)1097-0215(19991022)84:5<494::aid-ijc8>3.0.co;2-o
Up-regulation of ephrin-A1 during melanoma progression
Abstract
Ephrin-A1, formerly called B61, is a new melanoma growth factor; it is angiogenic and chemoattractant for endothelial cells. EPH-A2, or ECK (a receptor for ephrin-A1), is ectopically expressed in most melanoma cell lines; the pathology where this expression is first manifested and the possible role of the receptor in tumor progression are unknown. To determine these, we studied the expression of this ligand and receptor in biopsies of benign and malignant melanocytic lesions. EPH-A2 was not detected in normal melanocytes, benign compound nevi or advanced melanomas, though it was found in 2 of 9 biopsies of malignant melanoma in situ. Ephrin-A1 was present in occasional early lesions and in advanced primary melanomas (43%) and metastatic melanomas (67%). Expression of ephrin-A1 was induced in melanoma cells by pro-inflammatory cytokines. Our findings are consistent with 2 possible roles for ephrin-A1 in melanoma development: it may promote melanocytic cell growth or survival and induce vascularization in advanced melanomas. Both effects may be potentiated by inflammatory responses. Our data are consistent with earlier observations that an inflammatory infiltrate is associated with poor prognosis in thin primary melanomas.
Copyright 1999 Wiley-Liss, Inc.
Similar articles
-
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor epithelial cell kinase during melanoma progression.Cancer Res. 1995 Jun 15;55(12):2528-32. Cancer Res. 1995. PMID: 7780963
-
Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.Clin Cancer Res. 1998 Mar;4(3):791-7. Clin Cancer Res. 1998. PMID: 9533549
-
Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.Am J Pathol. 2002 Mar;160(3):1009-19. doi: 10.1016/S0002-9440(10)64922-X. Am J Pathol. 2002. PMID: 11891198 Free PMC article.
-
Roles of EphA1/A2 and ephrin-A1 in cancer.Cancer Sci. 2019 Mar;110(3):841-848. doi: 10.1111/cas.13942. Epub 2019 Feb 15. Cancer Sci. 2019. PMID: 30657619 Free PMC article. Review.
-
Cell-surface proteolysis, growth factor activation and intercellular communication in the progression of melanoma.Crit Rev Oncol Hematol. 2002 Oct;44(1):1-15. doi: 10.1016/s1040-8428(01)00196-2. Crit Rev Oncol Hematol. 2002. PMID: 12398996 Free PMC article. Review.
Cited by
-
Sustained small interfering RNA delivery by mesoporous silicon particles.Cancer Res. 2010 May 1;70(9):3687-96. doi: 10.1158/0008-5472.CAN-09-3931. Cancer Res. 2010. PMID: 20430760 Free PMC article.
-
Recanalization and remodeling of the great saphenous vein caused by the large melanoma's cutaneous metastasis.Contemp Oncol (Pozn). 2018;22(1):54-59. doi: 10.5114/wo.2018.74396. Epub 2018 Apr 3. Contemp Oncol (Pozn). 2018. PMID: 29692666 Free PMC article.
-
EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor.Cancer Immunol Immunother. 2010 May;59(5):759-67. doi: 10.1007/s00262-009-0796-2. Epub 2009 Nov 27. Cancer Immunol Immunother. 2010. PMID: 19943047 Free PMC article.
-
SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib.Cancers (Basel). 2019 May 14;11(5):673. doi: 10.3390/cancers11050673. Cancers (Basel). 2019. PMID: 31091806 Free PMC article.
-
EphA2 is a critical oncogene in melanoma.Oncogene. 2011 Dec 15;30(50):4921-9. doi: 10.1038/onc.2011.210. Epub 2011 Jun 13. Oncogene. 2011. PMID: 21666714 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous